unit 11: protein synthesis inhibitors

studied byStudied by 7 people
5.0(1)
Get a hint
Hint

Protein Synthesis Inhibitors

1 / 90

flashcard set

Earn XP

Description and Tags

91 Terms

1

Protein Synthesis Inhibitors

  • Selectively inhibit bacterial protein synthesis

    • by binding to and interfering with ribosomes

  • Basis for selective toxicity against microorganisms without causing major effects on mammalian cells

New cards
2

not identical

Protein synthesis in microorganisms is ___ to mammalian cells

New cards
3

70S

ribosomes in bacteria

New cards
4

80S

ribosomes in mammalians

New cards
5

Bacteriostatic

Mechanism of Action

They do not kill the bacteria but instead slow down the production of their proteins

New cards
6

Bactericidal

Mechanism of Action

They kill the bacteria

New cards
7

the charged tRNA unit carrying amino acid 6 binds to the acceptor site on the 70S ribosome

Mechanism of Action

Step 1

New cards
8

Transpeptidation: peptidyl tRNA at the donor site, with amino acids 1 through 5, then binds the growing amino acid chain to amino acid 6

Mechanism of Action

Step 2

New cards
9

uncharged tRNA left at the donor site is released

Mechanism of Action

Step 3

New cards
10

Translocation:

new 6-amino acid chain with its tRNA shifts to peptidyl site

Mechanism of Action

Step 4

New cards
11

Chloramphenicol & Macrolides

Mechanism of Action

  • inhibit the transpeptidation

  • bind to the 50S subunit

New cards
12

Macrolides, telithromycin, lincosamides

Mechanism of Action

block the translocation of your peptidyl tRNA from the acceptor

New cards
13

Tetracyclines

Mechanism of Action

  • bind to the 30S subunit

  • prevent step 1

New cards
14

Streptogramins

Mechanism of Action

constrict the exit channel

New cards
15

Linezolid

Mechanism of Action

  • block the formation of the tRNA ribosomes and the mRNA complex

  • blocks the binding of the mRNA and tRNA to the ribosome

    • difficult to form the peptide bonds

New cards
16

Active against both aerobic and anaerobic gram-positive and gram negative organisms

Chloramphenicol

Antimicrobial Activity

New cards
17

Plasmid-mediated - chloramphenicol acetyltransferases

Chloramphenicol

Resistance

New cards
18

Rickettsial infections

Chloramphenicol*: Clinical Use*

typhus and Rocky Mountain spotted fever

New cards
19

Alternative to a β-lactam antibiotic

Chloramphenicol*: Clinical Use*

treatment of bacterial meningitis occurring in patients who have major hypersensitivity reactions to penicillin

New cards
20

50-100 mg/kg/day divided every 6 hours

Chloramphenicol*: Pharmacokinetics*

usual dosage

New cards
21

chloramphenicol succinate (prodrug)

Chloramphenicol*: Pharmacokinetics*

IV formulation

New cards
22
  • conjugation with glucuronic acid

  • reduction to inactive aryl amines

Chloramphenicol*: Pharmacokinetics*

Inactivated by

New cards
23

Active chloramphenicol + inactive degradation products

Chloramphenicol*: Pharmacokinetics*

Excretion: urine

New cards
24

small amount of active drug

Chloramphenicol*: Pharmacokinetics*

Excretion: bile and feces

New cards
25

Gray baby syndrome

Chloramphenicol*: Toxicity*

Lacks effective glucuronic acid conjugation mechanism for the degradation and detoxification

New cards
26

gram-positive and gram-negative

Tetracyclines

Antimicrobial Activity

New cards
27
  • impaired influx or increased efflux

  • ribosome protection

  • enzymatic inactivation

Tetracyclines

Resistance

New cards
28
  • Mycoplasma pneumoniae

  • Chlamydiae Rickettsiae

  • Borrelia sp.

  • Vibrios some spirochetes

  • Anaplasma phagocytophilum

  • Ehrlichia sp

Tetracyclines

Primary Clinical Uses

New cards
29
  • community-acquired pneumonia (CAP)

  • syphilis

  • Chronic bronchitis

  • Leptospirosi

  • Acne

Tetracyclines

Secondary Clinical Uses

New cards
30

Tetracycline

Tetracyclines

Selective Uses: gastrointestinal ulcers caused by H. pylori

New cards
31

Demeclocycline

Tetracyclines

Selective Uses: ADH-­secreting tumors; inhibits the renal actions of antidiuretic hormone (ADH)

New cards
32

Minocycline

Tetracyclines

Selective Uses: meningococcal carrier state

New cards
33

Doxycycline

Tetracyclines: Clinical Use

  • Lyme disease

  • Malaria prophylaxis

  • amoebiasis

New cards
34

Tigecycline

Tetracyclines: Clinical Use

  • MRSA strains

  • VRE strains

New cards
35

60–70%

Tetracyclines: Pharmacokinetics

Oral Absorption: tetracycline and demeclocycline

New cards
36

95-100%

Tetracyclines: Pharmacokinetics

Oral Absorption: doxycycline and minocycline

New cards
37

Tigecycline and Eravacycline

Tetracyclines: Pharmacokinetics

poorly absorbed orally and must be administered intravenously

New cards
38

breast milk

Tetracyclines: Pharmacokinetics

Cross the placental barrier and excreted in ___

New cards
39

Doxycycline and tigecycline: feces

Tetracyclines: Pharmacokinetics

Excreted mainly in bile and urine except

New cards
40

Tetracycline (oral) - 6-8 hours

Tetracyclines: Pharmacokinetics

Short-acting

New cards
41

Demeclocycline (oral) - 12 hours

Tetracyclines: Pharmacokinetics

Intermediate-acting

New cards
42

Doxycycline & Minocycline (IV & Oral) - 16-18 hours

Tetracyclines: Pharmacokinetics

Long-acting

New cards
43

Tigecycline and Eravacycline

Tetracyclines: Pharmacokinetics

require twice daily dosing to maintain adequate serum concentrations

New cards
44

Omadacycline

Tetracyclines: Pharmacokinetics

dosed once daily after an initial loading dose

New cards
45

Nausea, vomiting, diarrhea

Tetracyclines*: Toxicity*

most common reasons for discontinuing tetracyclines

New cards
46

Fanconi syndrome: outdated

tetracyclines

Tetracyclines*: Toxicity*

Renal toxicity

New cards
47
  • Tetracycline + diuretic

  • Tetracycline and Minocycline

Tetracyclines*: Toxicity*

Nephrotoxicity

New cards
48

Demeclocycline

Tetracyclines*: Toxicity*

Photosensitivity

New cards
49

Doxycycline & Minocycline

Tetracyclines*: Toxicity*

Vestibular toxicity

New cards
50

Macrolides

  • moderate spectrum

  • macrocyclic lactone ring with attached sugars

  • good oral bioavailability

  • hepatic metabolism

New cards
51

Erythromycin

Macrolides

Prototype

New cards
52

Clarithromycin and azithromycin

Macrolides

Semisynthetic derivatives of erythromycin

New cards
53

Inhibition of protein synthesis occurs via binding to the 50S ribosomal RNA

Macrolides

Mechanism of Action

New cards
54

torsades de pointes arrhythmia

Macrolides

Macrolide antibiotics prolong the electrocardiographic QT interval due to an effect on potassium channels

New cards
55

2 hours (Oral & IV)

Erythromycin

Half Life

New cards
56
  1. Reduced permeability of the cell membrane or active efflux

  2. Production (by Enterobacteriaceae) of esterases that hydrolyze macrolides

  3. Modification of the ribosomal binding site (so-called ribosomal protection) by chromosomal mutation or by a macrolideinducible or constitutive methylase

Erythromycin

Resistance

New cards
57

Food

Erythromycin: Pharmacokinetics

interferes with absorption

New cards
58

bile

Erythromycin: Pharmacokinetics

Excretion

New cards
59

polymorphonuclear leukocytes and macrophages

Erythromycin: Pharmacokinetics

Taken up by ___

New cards
60

penicillin substitute in penicillin-allergic individuals with infections caused by staphylococci and streptococci

Erythromycin

Clinical Use

New cards
61

Clarithromycin

Macrolides

More active against Mycobacterium avium complex

New cards
62

6 hours (Oral)

Clarithromycin

Half-life

New cards
63

14-hydroxyclarithromycin with antibacterial activity

Clarithromycin: Pharmacokinetics

eliminated in the urine

New cards
64

patients with creatinine clearances less than 30 mL/min

Clarithromycin: Pharmacokinetics

Dosage reduction

New cards
65

Azithromycin

Macrolides

  • Spectrum of activity, mechanism of action, and clinical uses are similar to those of clarithromycin

  • M avium complex, T gondii, H influenzae, Chlamydia sp

New cards
66

2-4 days (Oral & IV)

Azithromycin

Half-life

New cards
67

Aluminum and magnesium antacids

Azithromycin: Pharmacokinetics

do not alter bioavailability but delay absorption and reduce peak serum concentrations

New cards
68

Clindamycin

  • Chlorine-substituted derivative of lincomycin (Streptomyces lincolnensis)

  • Gram-negative aerobes are intrinsically resistant

New cards
69

6-8 hours (Oral & IV)

Clindamycin

Half-life

New cards
70

severe anaerobic infections

Clindamycin*: Clinical Use*

Bacteroides, Fusobacterium, and Prevotella

New cards
71

Backup drug against gram-positive cocc

Clindamycin*: Clinical Use*

Community-acquired strains of MRSA

New cards
72

Toxic shock syndrome

Clindamycin*: Clinical Use*

with penicillin G

New cards
73

Penetrating wounds of the abdomen and gut

Clindamycin*: Clinical Use*

combined with aminoglycoside or cephalosporin

New cards
74

endocarditis in valvular disease

Clindamycin*: Clinical Use*

patients allergic to penicillin

New cards
75

P. jiroveci pneumonia in AIDS patients

Clindamycin*: Clinical Use*

In combination with primaquine alternative

New cards
76

AIDS-related toxoplasmosis

Clindamycin*: Clinical Use*

In combination with pyrimethamine

New cards
77

Quinupristin-Dalfopristin

Streptogramins

Combination streptogramins

New cards
78

gram-positive cocci

Streptogramins: Quinupristin-Dalfopristin

active against ___

New cards
79

0.85 hours

Streptogramins: Quinupristin-Dalfopristin

Quinupristin half-life

New cards
80

0.7 hours

Streptogramins: Quinupristin-Dalfopristin

Dalfopristin half-life

New cards
81

feces

Streptogramins: Quinupristin-Dalfopristin

Excretion

New cards
82

Linezolid

Oxazolidinones

  • Active against gram-positive organisms

  • Bacteriostatic but bactericidal against streptococci

  • binds to 23S ribosomal RNA of the 50S subunit

New cards
83

4-6 hours (Oral & IV)

Linezolid

Half-life

New cards
84

thrombocytopenia

Linezolid

most common manifestation

New cards
85

Tedizolid

Oxazolidinones

  • Active moiety of the prodrug tedizolid phosphate

  • High potency against gram-positive bacteria

New cards
86

Plasma concentrations

Tedizolid: Pharmacokinetics

good indicator for tissue concentrations as it penetrates well into muscle, adipose, and pulmonary tissues

New cards
87

12 hours

Tedizolid

Half-life

New cards
88

Pleuromutilins

discovered in the 1950s but previously it was only used in veterinary medicine.

New cards
89

Lefamulin

Pleuromutilins

  • Approved only for the treatment of adult patients with community acquired pneumonia

  • lower respiratory tract infections

  • in vitro activity against most aerobic gram-positive organisms

New cards
90

hepatic metabolism (CYP3A4)

Lefamulin

Excretion

New cards
91

8 hours, 2x daily

Lefamulin

Half-life

New cards

Explore top notes

note Note
studied byStudied by 132 people
... ago
5.0(1)
note Note
studied byStudied by 55 people
... ago
4.5(2)
note Note
studied byStudied by 7 people
... ago
5.0(1)
note Note
studied byStudied by 30 people
... ago
5.0(1)
note Note
studied byStudied by 37 people
... ago
5.0(1)
note Note
studied byStudied by 6 people
... ago
5.0(1)
note Note
studied byStudied by 16 people
... ago
5.0(1)
note Note
studied byStudied by 23129 people
... ago
4.8(187)

Explore top flashcards

flashcards Flashcard (21)
studied byStudied by 4 people
... ago
5.0(1)
flashcards Flashcard (93)
studied byStudied by 13 people
... ago
5.0(2)
flashcards Flashcard (27)
studied byStudied by 5 people
... ago
5.0(1)
flashcards Flashcard (58)
studied byStudied by 4 people
... ago
5.0(1)
flashcards Flashcard (83)
studied byStudied by 8 people
... ago
5.0(1)
flashcards Flashcard (30)
studied byStudied by 1 person
... ago
5.0(1)
flashcards Flashcard (22)
studied byStudied by 2 people
... ago
5.0(1)
flashcards Flashcard (68)
studied byStudied by 29 people
... ago
5.0(2)
robot